Key Takeaways Tractor Supply is projected to post Q3 revenues of $3.72B, up 7.2% year over year.EPS is estimated at 48 cents, up 6.7% from last year, reflecting steady bottom-line improvement.Growth in C.U.E. products, loyalty gains and digital expansion are set to fuel TSCO's performance.Tractor Supply Company (TSCO) is likely to register an increase in its top and bottom lines when it reports third-quarter 2025 results on Oct. 23, before market open. The Zacks Consensus Estimate for revenues is pegged at ...

Core Insights - Pacific Biosciences of California (PACB) reported revenue of $39.77 million for the quarter ended June 2025, marking a year-over-year increase of 10.4% and exceeding the Zacks Consensus Estimate by 9.06% [1] - The company posted an EPS of -$0.13, an improvement from -$0.20 a year ago, with a surprise of 27.78% compared to the consensus estimate of -$0.18 [1] Revenue Breakdown - Revenue from Product - Instrument was $14.15 million, slightly below the average estimate of $10.9 million, reflecting a year-over-year decline of 3.7% [4] - Revenue from Product was $33.08 million, surpassing the average estimate of $31.18 million, with a year-over-year increase of 4.2% [4] - Revenue from Service and other reached $6.68 million, significantly exceeding the estimated $5.09 million, representing a year-over-year increase of 56.6% [4] - Revenue from Product - Consumable was $18.93 million, below the average estimate of $20.29 million, but still showing a year-over-year growth of 11.4% [4] Stock Performance - Shares of Pacific Biosciences have declined by 6.8% over the past month, contrasting with a 1.2% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Pacific Biosciences of California (PACB) reported a revenue of $37.15 million for the quarter ended March 2025, reflecting a decrease of 4.3% year-over-year, but exceeding the Zacks Consensus Estimate by 6.15% [1] - The company's EPS was -$0.15, an improvement from -$0.26 in the same quarter last year, and surpassed the consensus EPS estimate of -$0.19 by 21.05% [1] Revenue Breakdown - Revenue from Product-Instrument was $11 million, falling short of the estimated $12.21 million, marking a significant decline of 42.1% year-over-year [4] - Revenue from Product reached $31.11 million, slightly above the estimated $30.90 million [4] - Revenue from Service and other sources was $6.04 million, exceeding the estimated $4.97 million, representing a substantial increase of 58.9% year-over-year [4] - Revenue from Product-Consumable was $20.10 million, surpassing the average estimate of $18.69 million, with a year-over-year growth of 25.6% [4] Stock Performance - Over the past month, shares of Pacific Biosciences have declined by 22.1%, contrasting with the Zacks S&P 500 composite's increase of 11.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]